For many pathologies such as cancer or neurological disorders, it has been found that Histone Deacetylase (HDAC) activity is disrupted, making them promising targets for drug development. Scientists need access to a broade range of products ( Active Enzyme, inhibitors/activators, Biochemical screening assays…), to simplify their research and identification of HDAC inhibitors.
TIGIT:CD155/CD112 immune inhibition (in green)
Over the last several years, the Immune System has appeared as a central, priority target to fight cancer and various other diseases. Currently, in cancer treatment most of the Immunotherapeutic successes, are molecules developed to modulate and restore immune response by targeting critical Immune Checkpoints.
Some of them can activate T Cells, and on the opposite, some can inhibit this response against cancer cells, such as PD-1 and CTLA4, two of the most studied Immune Checkpoints. The majority of the popular molecules approved in Immunotherapy which have led to clinical benefits, are antibodies inhibiting immune checkpoint activities, such for PD1 with nivolumab and pembrolizumab, or CTLA4 with ipilumab.
BPS Bioscience’s full range of products are available through tebu-bio in Europe.
As a regulator of the immune system, Immune checkpoints appear to be privileged targets In Drug Discovery and Immunotherapy research. Indeed, promising molecules tested in clinical trials and approved are giving new hope for cancer treatment. Beyond checkpoint receptors, the Enzymatic pathway also regulates the immune system and provides additional targets for Drug Development, and may increase the chances of clinical success in Cancer treatment.
In addition to already developed Immune Checkpoint Reporter cell lines (as introduced in my previous post), BPS Bioscience also provide tools to study the enzymatic pathway, such as the tryptophan catabolism pathway controlled by IDO1: The IDO / TDO pathway.
Top contributors
